top of page

Chchd10 protein's regulation of adipose tissue suggests new obesity management strategies

owenhaskins

Researchers from the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine at the University of Hong Kong (HKUMed), identified the mitochondria protein Chchd10 as a novel regulator of adipose tissue homeostasis, offering new insights into the management of obesity and its related metabolic disorders.


Summary of the effect of Chchd10 reduction in adipocytes in response to excess energy intake. Credit: Advanced Science (2025). DOI: 10.1002/advs.202408763
Summary of the effect of Chchd10 reduction in adipocytes in response to excess energy intake. Credit: Advanced Science (2025). DOI: 10.1002/advs.202408763

The health of adipose tissue is crucial for maintaining the body's energy balance and metabolic health. In response to excess energy intake, adipose tissue undergoes remodelling by increasing the number and size of fat cells. However, an imbalance in this remodelling process can lead to obesity and related metabolic disorders.


The accumulation of fat in adipose depots in different anatomical locations can lead to distinct metabolic outcomes. Excessive visceral adipose tissue is a risk factor for metabolic complications, but lipid storage in subcutaneous adipose tissue is considered less harmful. Understanding the molecular mechanisms that govern adipose tissue homeostasis is therefore essential for developing effective interventions.


The HKUMed research team investigated the role of Chchd10 in adipose tissue remodeling using high-fat diet (HFD)-induced wild-type and adipose tissue-specific Chchd10 (AT-Chchd10)-deficient mice. The study found that in HFD-induced mice, the levels of Chchd10 were significantly reduced in white adipose tissue, which is responsible for energy storage and metabolism regulation. This reduction accelerated subcutaneous fat formation in the mice, allowing them to store more energy during short-term, high-fat diet periods.


Conversely, the absence of Chchd10 resulted in elevated levels of GSTA4, a protein found in visceral fat tissue that is essential for helping clear harmful lipid peroxidation products, preventing protein carbonylation and cellular dysfunction after long-term, high-fat diet consumption. The study highlighted that the downregulation of Chchd10 activates the NRF2 signalling pathway, which promotes subcutaneous fat formation and GSTA4 expression.


The findings demonstrate that Chchd10 is a novel regulatory factor that maintains stability and balance in adipose tissue and that downregulation of Chchd10 enhances subcutaneous fat formation and regulates antioxidant capacity mainly in visceral adipose tissue, thereby reducing the risk of obesity and metabolic disorders induced by diet.


Additionally, in mice undergoing weight gain from a high-fat diet, knocking out Chchd10 in adipose tissue significantly reduced the increase in visceral fat mass, suggesting that regulating Chchd10 levels could be a potential therapeutic strategy for treating obesity.


"This study provides valuable insights into the molecular pathways involved in regulating adipose tissue homeostasis and their implications for obesity management,” explained Professor Ruby Hoo Lai-chong, Associate Professor in the Department of Pharmacology and Pharmacy, HKUMed. “By targeting Chchd10 and its associated pathways, new therapeutic strategies can be developed to combat diet-induced obesity and improve metabolic health. The research underscores the potential interventions targeting metabolic dysfunctions in specific adipose depots."


In an earlier study, ‘Islet‐Resident Memory T Cells Orchestrate the Immunopathogenesis of Type 1 Diabetes through the FABP4‐CXCL10 Axis’, also published in Advanced Science, Hoo's research team uncovered the role of tissue-resident memory T (TRM) cells in the development of type 1 diabetes. The study explored how TRM cells, through the fatty acid-binding protein 4 (FABP4) and the inflammatory chemokine CXCL10, orchestrate the recruitment of cytotoxic T cells to pancreatic islets, thereby playing a significant role in the onset of type 1 diabetes.


The research demonstrated that genetic deletion of FABP4 or depletion of TRM cells in non-obese diabetic mice led to reduced cytotoxic T cell recruitment, delayed diabetes onset, and suppressed chemokine CXCL10 production. These findings suggest that targeting FABP4 could offer a promising therapeutic strategy for managing type 1 diabetes by mitigating immune-mediated damage to pancreatic cells.


The findings were featured in the paper, ‘Chchd10: A Novel Metabolic Sensor Modulating Adipose Tissue Homeostasis’, published in Advanced Science. To access this paper, please click here

 

Commentaires


Weekly Digest

Get a round-up of the main headlines from Bariatric News, directly to your inbox each week.

Thanks for submitting!

Get in touch!
Email: info@bariatricnews.net

©2023 Dendrite Clinical Systems Ltd. All rights reserved.
No part of this website may be reproduced, stored in a retrieval system, transmitted in any form or by any other means without prior written permission from the Managing Editor. The views, comments and opinions expressed within are not necessarily those of Dendrite Clinical Systems or the Editorial Board. Bariatricnews.net is a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

bottom of page